NCT Number: NCT06696027
The AYLo study (AutoimmunitY and Loss of y - Investigating the Role of Hematopoietic Mutations and Mosaic Mutation in the Y Chromosome in Autoimmune Rheumatologic Diseases) aims to systematically investigate hematopoietic mutations, such as hematopoietic (mosaic) loss of the Y chromosome (mLOY), focusing on their underlying causes, pathophysiological significance, patterns of manifestation, and impact on disease progression in autoimmune, rheumatologic disorders. This research seeks to bridge existing knowledge gaps by exploring how such mutations influence immune homeostasis, cellular function, and susceptibility to inflammation-driven pathologies.
Through the integration of advanced immunological profiling, the study aspires to uncover key mechanisms that drive the initiation, progression, and complications of autoimmune rheumatic diseases. These analyses will combine single nucleotide polymorphisms (SNP) arrays, multiplex assays, transcriptomics, and flow cytometry staining of peripheral blood mononuclear cells to delineate the interplay between hematopoietic mutations and immune dysregulation.
A further objective is the development of a multimodal framework for disease-specific characterization, enabling precise mapping of mutation-driven phenotypes across diverse autoimmune conditions. This framework will incorporate clinical, molecular, and imaging data.
Additionally, the AYLo study aims to explore the potential role of mLOY and other hematopoietic mutations as biomarkers for disease stratification, prognosis, and therapeutic response. The findings may open avenues for personalized treatment approaches, leveraging the molecular insights to inform targeted interventions and improve patient outcomes in autoimmune rheumatic disorders.
By integrating translational and basic science approaches, this study has the potential to redefine current paradigms in autoimmune disease research and therapy.
Interested in participating?
Request Info50 year and older
Male
Observational
Bonn, North Rhine-Westphalia, 53127, Germany
Location status: Recruiting
Raul Nicolas Jamin, MD
SUB_INVESTIGATOR
Sebastian Zimmer, MD
SUB_INVESTIGATOR
Simon Michael Petzinna, MD
SUB_INVESTIGATOR
Valentin Sebastian Schäfer, MD
CONTACT
Valentin Sebastian Schäfer, MD
PRINCIPAL_INVESTIGATOR
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Inclusion criteria
(Healthy controls):
Exclusion criteria
(Healthy controls):
Utilizing single nucleotide polymorphisms (SNP) genotyping mosaic loss of y (mLOY) of individual patient will be assessed.
3'mRNA sequencing analyzes gene expression profiles related to the immune response in different study cohorts, aiding in understanding the genetic underpinnings of inflammation and its association with mLOY.
Used to measure cytokine levels in the serum of investigated patients, aiding in profiling inflammatory markers that are indicative of disease activity, response to treatment and consequence of mLOY..
Employed to analyze immune cell phenotypes in investigated cohorts. This test helps identify various immune cell subsets and their activation states, which are critical for understanding disease mechanisms and its association with mLOY.
Serum Chemistry
Results of routine clinical assessment of pulmonary involvement (such as lung ultrasound, computed tomography, chest x-ray, whole-body plethysmography) will be compared to mLOY, ELISA/ Legendplex/ flow cytometry/ transcriptome analysis results.
Time frame: Cross sectional. Newly diagnosed patients: At baseline and 12 months after diagnosis).
Detection and quantification of the fraction of hematopoietic cells exhibiting mLOY in peripheral blood using SNP. Unit of Measure: Percentage (%).
Time frame: Cross sectional. Newly diagnosed patients: At baseline and 12 months after diagnosis
Identification and quantification of immune cell subtypes, using flow cytometry.
Unit of Measure: Changes in levels (percentages).
Time frame: Cross sectional. Newly diagnosed patients: At baseline and 12 months after diagnosis
Identification and quantification of cytokines using 3'-mRNA transcriptome analysis and ELISA/ Legendplex. Unit of Measure: Changes in levels (pg/mL)
Time frame: Cross sectional. Newly diagnosed patients: At baseline and 12 months after diagnosis
Detection of structural anomalies in the lung in clinical routine assessment using lung ultrasound, computed tomography, chest radiography and whole-body plethysmography. Unit of Measure: Number of participants.
Contact information is provided by the study sponsor or research team.
Simon Michael Petzinna, MD
CONTACT
Valentin Sebastian Schäfer, MD
CONTACT
University of Bonn
Other
Investigating the Role of Hematopoietic Mutations and Mosaic Mutation in the Y Chromosome in Autoimmune Rheumatologic Diseases
Acronym: AYLo
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07150000
ANCA Associated Vasculitis (AAV), Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Bonn, North Rhine-Westphalia, Germany
View Trial DetailsNCT06766552
Ankylosing Spondylitis (AS), Ankylosis
Hangzhou, China
View Trial DetailsNCT06763783
Arteritis, Arthritis
Lund, Sweden
View Trial DetailsNCT05193396
Adrenal Gland Diseases, Adrenal Insufficiency
Aarhus, Denmark
View Trial Details